Published in TB and Outbreaks Week, September 9th, 2008
"We'd characterize VaxInnate's M2e universal influenza vaccine candidate as very promising, based upon the immune responses and tolerability we saw in the clinical trial participants," said Christine Turley, MD, Director of clinical trials and clinical research at the Sealy Center for Vaccine Development, University of Texas Medical Branch (UTMB), and the study's primary investigator. "UTMB is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week